Crural Repair During Laparoscopic Sleeve Gastrectomy in Patients With a Lax Gastroesophageal Junction
Launched by SENGKANG GENERAL HOSPITAL · Apr 10, 2022
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether repairing a hiatal hernia at the same time as laparoscopic sleeve gastrectomy (LSG) can help reduce the chance of developing erosive esophagitis (EE) after surgery. LSG is a popular weight-loss surgery, but some patients experience gastroesophageal reflux disease (GERD) and EE afterwards, especially if they have a condition called a lax gastroesophageal junction. The researchers want to see if fixing the hiatal hernia, which can weaken the valve between the stomach and esophagus, can lower these risks.
To participate in this study, you need to be between 21 and 65 years old, able to give informed consent, and diagnosed with a specific type of gastroesophageal junction issue during a preoperative endoscopy. If you join, you will be randomly assigned to either have just the LSG or to also have the hiatal hernia repaired. The study will track your recovery over a year, looking at symptoms, quality of life, and any complications. This could be important for expanding treatment options for patients who might benefit from LSG but are at risk for EE.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 21-65 years old
- • Able to provide informed consent
- • Hill's grade III gastroesophageal junction on preoperative endoscopy
- • Opted to undergo laparoscopic sleeve gastrectomy as their bariatric procedure
- Exclusion Criteria:
- • Unable or unwilling to provide informed consent
- • Contraindications to laparoscopic sleeve gastrectomy
- • Opted not to undergo laparoscopic sleeve gastrectomy
- • Had previous upper gastrointestinal surgery
- • Had documented erosive esophagitis on preoperative endoscopy
- • Had Hill's grade I, II or IV gastroesophageal junction on preoperative endoscopy
About Sengkang General Hospital
Sengkang General Hospital (SKGH) is a leading healthcare institution in Singapore, dedicated to providing comprehensive medical services and advancing clinical research to enhance patient care. As a key player in the region's healthcare landscape, SKGH is committed to fostering innovation through clinical trials that explore new therapies and treatments. The hospital is equipped with state-of-the-art facilities and a multidisciplinary team of experienced healthcare professionals, ensuring a robust environment for conducting high-quality research. By prioritizing ethical standards and patient safety, Sengkang General Hospital aims to contribute significantly to the global medical community and improve health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Singapore, , Singapore
Patients applied
Trial Officials
Baldwin Po Man Yeung, MBChB, FRCS
Principal Investigator
Sengkang General Hospital
Jeremy Tian Hui Tan, MBBS, FRACS
Principal Investigator
Singapore General Hospital
Koy Min Chue, MBBS, FRCSEd
Principal Investigator
Sengkang General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials